Rabbit Anti-PBRM1 Recombinant Antibody (CBYC-P187) (CBMAB-P0921-YC)

Yamashita, N., Morimoto, Y., Fushimi, A., Ahmad, R., Bhattacharya, A., Daimon, T., ... & Kufe, D. (2023). MUC1-C dictates PBRM1-mediated chronic induction of interferon signaling, DNA damage resistance, and immunosuppression in triple-negative breast cancer. Molecular Cancer Research, 21(3), 274-289.

Walton, J., Lawson, K., Prinos, P., Finelli, A., Arrowsmith, C., & Ailles, L. (2023). PBRM1, SETD2 and BAP1—the trinity of 3p in clear cell renal cell carcinoma. Nature Reviews Urology, 20(2), 96-115.

Petell, C. J., Burkholder, N. T., Ruiz, P. A., Skela, J., Foreman, J. R., Southwell, L. E., ... & Strahl, B. D. (2023). The bromo-adjacent homology domains of PBRM1 associate with histone tails and contribute to PBAF-mediated gene regulation. Journal of Biological Chemistry, 299(8).

Chabanon, R. M., Morel, D., Eychenne, T., Colmet-Daage, L., Bajrami, I., Dorvault, N., ... & Postel-Vinay, S. (2021). PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer. Cancer research, 81(11), 2888-2902.

Karki, M., Jangid, R. K., Anish, R., Seervai, R. N., Bertocchio, J. P., Hotta, T., ... & Tripathi, D. N. (2021). A cytoskeletal function for PBRM1 reading methylated microtubules. Science advances, 7(14), eabf2866.

Liu, X. D., Kong, W., Peterson, C. B., McGrail, D. J., Hoang, A., Zhang, X., ... & Jonasch, E. (2020). PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nature communications, 11(1), 2135.

Carril-Ajuria, L., Santos, M., Roldán-Romero, J. M., Rodriguez-Antona, C., & de Velasco, G. (2019). Prognostic and predictive value of PBRM1 in clear cell renal cell carcinoma. Cancers, 12(1), 16.

Porter, E. G., Dhiman, A., Chowdhury, B., Carter, B. C., Lin, H., Stewart, J. C., ... & Dykhuizen, E. C. (2019). PBRM1 regulates stress response in epithelial cells. Iscience, 15, 196-210.

Cai, W., Su, L., Liao, L., Liu, Z. Z., Langbein, L., Dulaimi, E., ... & Yang, H. (2019). PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nature communications, 10(1), 5800.

Braun, D. A., Ishii, Y., Walsh, A. M., Van Allen, E. M., Wu, C. J., Shukla, S. A., & Choueiri, T. K. (2019). Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma. JAMA oncology, 5(11), 1631-1633.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols